TGFB1 and diabetic kidney disease: In experimental models of diabetic nephropathy, Mefunidone (MFD) treatment reduces ROS generation, suppresses TGF-β1/Smad pathway activation, and inhibits epithelial-mesenchymal transition (EMT) (120).